Although the benefit of B-RAF inhibition as monotherapy has been sufficiently confirmed, rapidly occuring secondary resistance mechanisms in tumors will most likely favor combination therapies targeting other genetic “hot spots” in melanoma such as MEK, RAS, and KIT. This evidence concerns the gene BRAF and melanoma.